SAINTS SAGES Surgical Completes Series B Financing Led by Qiming Venture Partners
Shanghai-based SAINTS SAGES Surgical announces the completion of Series B financing led by Qiming Venture Partners for the development, global commercialisation and construction of new automation facilities for its surgical energy devices.
Founded in 2017, Shanghai-based SAINTS SAGES Surgical aims to become a leader in the field of minimally invasive devices. In March 2021, SAINTS SAGES Surgical closed a Series A financing of over RMB 100 million led by Qiming Venture Partners.
In 2021, its SanAgile™ SA01 Ultrasonic Surgical System was approved by China’s National Medical Products Administration (NMPA) as a Class III device which is designed to transect, dissect and coagulate tissue in the general, plastic, gynecologic, urologic, thoracic surgeries, and other open or laparoscopic procedures. The SAG01 Generator is loaded with RTTE I (Real Time Tissue Effect) algorithm, which enables real-time energy to react in response to the tissue effect throughout the whole process for high performance in tissue cutting, tissue coagulation and blood vessel closure. It had been used by more than 100 tier 3A hospitals for nearly 10,000 surgeries.
The SanAgile™ SA10 SASD Ultrasonic Surgery Advanced System, which features a controller in place of the traditional power supply mainframe, was approved by NMPA in September 2022 to significantly reduce costs for healthcare providers. Equipped with RTTE II (Real Time Tissue Effect 2nd Generation) algorithm, this upgrade pre-monitors tissue volume and optimizes energy parameters to maximize intraoperative smoothness.
The Post is Available in: English – 简体中文
Português 
English (UK) 
Deutsch 
简体中文 
Français 
日本語 
Español 
Nederlands 
Polski 
Italiano 
한국어 
Русский 
